Drug profile · INN
vildagliptin
GALVUS
vildagliptin (GALVUS) is a dipeptidyl peptidase iv inhibitor. Associated with Novartis Pharmaceuticals.
EMA: approved TGA: approved Alimentary tract and metabolism (A10) A10BH02
Patents linked 1
Pipeline programs 5
News articles 0
Drug details — vildagliptin
- Class
- Alimentary tract and metabolism (A10)
- Route
- —
- Patents
- 1
- Programs
- 5
- Data quality
- 0.83
Quick answer
vildagliptin (GALVUS) is a dipeptidyl peptidase iv inhibitor. Associated with Novartis Pharmaceuticals.
Key facts
INN vildagliptin
Brand GALVUS
Mechanism Dipeptidyl peptidase IV inhibitor
Target Dipeptidyl peptidase 4
Therapeutic class Alimentary tract and metabolism (A10)
ATC code A10BH02
Originator Novartis Pharmaceuticals
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Primary target: Dipeptidyl peptidase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is vildagliptin?
vildagliptin (GALVUS) is a dipeptidyl peptidase iv inhibitor. Associated with Novartis Pharmaceuticals.
What is the brand name for vildagliptin?
GALVUS is a marketed brand name for vildagliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.